BrightGene Submits HKEX Prospectus, Aiming for Main‑Board Listing
CompanyDeals

BrightGene Submits HKEX Prospectus, Aiming for Main‑Board Listing

Dizal Pharmaceutical Reports 73% Revenue Growth, Driven by Sunvozertinib and Golidocitinib
Company

Dizal Pharmaceutical Reports 73% Revenue Growth, Driven by Sunvozertinib and Golidocitinib

JW Therapeutics & Regeneron Sign Expanded TCR‑T Collaboration, Unlocking $50 Million in Funding
CompanyDeals

JW Therapeutics & Regeneron Sign Expanded TCR‑T Collaboration, Unlocking $50 Million in Funding

Novo Nordisk Launches $9 Billion Unsolicited Bid for Metsera, Triggering Battle with Pfizer
CompanyDeals

Novo Nordisk Launches $9 Billion Unsolicited Bid for Metsera, Triggering Battle with Pfizer

Thermo Fisher Secures $8.875B Clario Acquisition, Enhancing Digital‑Trial Endpoint Suite
CompanyDeals

Thermo Fisher Secures $8.875B Clario Acquisition, Enhancing Digital‑Trial Endpoint Suite

ModeX Therapeutics Partners With Regeneron on Multispecific Antibody Platform
CompanyDeals

ModeX Therapeutics Locks $1 B+ Collaboration With Regeneron on Multispecific Antibody Technology

Everest Medicines Secures Exclusive Rights to VIS‑101 in Greater China, Potential 2026 Phase 3 Launch
CompanyDeals

Everest Medicines Secures Exclusive Rights to VIS‑101 in Greater China, Potential 2026 Phase 3 Launch

Bayer Secures FDA Approval for Elinzanetant, First Dual NK Therapy for VMS
CompanyDrug

Bayer Secures FDA Approval for Elinzanetant, First Dual NK Therapy for VMS

Ascletis Launches ASC36, a Once‑Monthly Injectable Targeting Obesity
CompanyDrug

Ascletis Launches ASC36, a Once‑Monthly Injectable Targeting Obesity

Pharmaron Expands CRO Footprint with 82.5% Acquisition of Biortus in $200 M Deal
CompanyDeals

Pharmaron Expands CRO Footprint with 82.5% Acquisition of Biortus in $200 M Deal

Sihuan Pharmaceutical Partners with Abalone Bio to Accelerate Obesity Therapeutics Development
CompanyDeals

Sihuan Pharmaceutical Partners with Abalone Bio to Accelerate Obesity Therapeutics Development

MediCare Negotiation Begins: 535 Generic Drugs Reviewed for 2025 Drug Catalogue
Policy / Regulatory

MediCare Negotiation Begins: 535 Generic Drugs Reviewed for 2025 Drug Catalogue